explore -WSS

explore

author：hotspot 2025-08-11 11:43:55 - browse：9275

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： My daughter's legacy lives on through her writing, phage therapy

Wikipedia

WSS

Senate panel passes drug pricing bills, but drops one PBM reform

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Novo pauses ads for weight loss drug Wegovy amid demand

Living organ donors deserve priority status for transplants

Can medical device makers keep up in the race to treat obesity?

hotspot

explore

leisure time

Virginia high school admissions case could be legal follow

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Apple is now the first public company to be valued at $3 trillion

California wildfire smoke linked to 52,000 early deaths, study says

In age of alternative facts, a scholarly course on calling out crap

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Walensky prepares to leave CDC — and Congress — behind

5 takeaways from STAT's examination of Zynex Medical

Wildfire smoke exposes gaps in outdoor worker protections

Novo pauses ads for weight loss drug Wegovy amid demand

hotspot

Deposition: Sackler embraced plan to conceal OxyContin’s strength

How faith leaders like me can help address America's obesity epidemic

STAT Virtual Event: ASCO Recap, Live!

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Readers discuss the intersection of pregnancy and addiction

hotspot

focus

Wikipedia

entertainment